*March 2022*
This is a Phase II randomized trial of carboplatin + pemetrexed + bevacizumab with or without atezolizumab in stage 4 non-squamous NSCLC patients who harbor a sensitizing EGFR mutation or have never smoked. Learn more here.
*March 2022*
This is a Phase II randomized trial of carboplatin + pemetrexed + bevacizumab with or without atezolizumab in stage 4 non-squamous NSCLC patients who harbor a sensitizing EGFR mutation or have never smoked. Learn more here.